Tirzepatide, a new once-weekly GIP/GLP-1 medication, is now in phase 3 testing for blood glucose management and chronic weight management in individuals with type 2 diabetes. GIP is a hormone that may help GLP-1 receptor agonists work better, and has been found in early testing to reduce food intake while increasing energy expenditure, resulting in weight loss. Read more